{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-012517","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.523106+00:00","generated_at":"2026-06-24T02:31:55.869393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TG Therapeutics Q2 net loss $40.5M, down from $78.5M YoY; cash $231.8M","bullets":["Net loss of $40.5M in Q2 2022 vs $78.5M in Q2 2021; six-month loss $109.5M vs $169.1M.","R&D expenses $26.9M (Q2 2022) vs $44.9M (Q2 2021), down on cost-saving measures and UKONIQ withdrawal.","Cash & investments $231.8M at June 30, 2022; expected to fund operations into H2 2023.","PDUFA goal date for ublituximab in RMS set for December 28, 2022; preparing for potential early 2023 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-012517","json":"https://secwatch.observer/filing/0001558370-22-012517.json","markdown":"https://secwatch.observer/filing/0001558370-22-012517.md","text":"https://secwatch.observer/filing/0001558370-22-012517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022012517/0001558370-22-012517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022012517/tgtx-20220808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:31:55.869393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}